First U.S. Implants of Newly Approved Embozene(TM) Color-Advanced Microspheres Embolizatio... ( NEWNAN Ga. Dec. 31 /- Against the...)

First U.S. Implants of Newly Approved Embozene(TM) Color-Advanced Microspheres Embolization Platform

Date:12/31/2008

NEWNAN, Ga., Dec. 31 /PRNewswire/ -- Against the backdrop of a flagging economy, bailouts, and bleak predictions, there is a biotechnology firm in suburban Atlanta with a future as bright as New Year's Eve fireworks. Only days after receiving FDA approval to market the Embozene(TM) Color-Advanced Microspheres embolization platform for the treatment of hypervascularized tumors (tumors with a large number of blood vessels in many locations) and arteriovenous malformations (defects in the circulatory system), CeloNova BioSciences today announced that the product has been successfully used to treat several patients at two Atlanta area hospitals: Emory-Adventist Hospital in Smyrna and WellStar Windy Hill Hospital in Marietta.

(Photo: http://www.newscom.com/cgi-bin/prnh/20081231/CLW031-a )

(Photo: http://www.newscom.com/cgi-bin/prnh/20081231/CLW031-b )

(Logo: http://www.newscom.com/cgi-bin/prnh/20081001/CLW080LOGO-b )

Dr. John Lipman, who performed the procedures at both hospitals, said, "I was really impressed with the Embozene(TM) Color-Advanced Microspheres. The material handled well, going immediately into suspension and, importantly, staying in suspension. The fact that Embozene(TM) Microspheres are color coded to size is an appealing feature that allows good visibility of the material and clearly creates a higher and important safety profile. CeloNova has apparently carefully engineered these beads to be extremely 'friendly' for the physician to use. I found in these first patients that the product was highly manageable during the procedure. I achieved the procedural goals to devascularize the tumors quickly, using much less material tha
'/>"/>

0

GOOD

Page: 1 2 3 4
Related biology technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. GlaxoSmithKline Recognizes University of Michigans Dr. Daniel F. Hayes as the First Recipient of the Gianni Bonadonna Breast Cancer Award
3. Kewaunee Scientific Announces First Quarter Results and Quarterly Dividend
4. Genmab Announces 2007 First Half Year Results
5. Pharsight Achieves First License Sale for Public-Source Database
6. Novare Announces First Ever Single Port Laparoscopic Kidney Removal (Nephrectomy) Using RealHand(TM) HD Instruments
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. China Medical Technologies Reports First Quarter Financial Results
9. Pressure BioSciences, Inc. Issued First Patent in Canada
10. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
11. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer

Post Your Comments:

First U.S. Implants of Newly Approved Embozene(TM) Color-Advanced Microspheres Embolizatio...( NEWNAN Ga. Dec. 31 /- Against the...)